Abstract:Research on CAR T cells has achieved enormous progress in recent years. After the impressive results obtained in relapsed and refractory B-cell acute lymphoblastic leukemia and aggressive B-cell lymphomas, two constructs, tisagenlecleucel and axicabtagene ciloleucel, were approved by FDA. The role of CAR T cells in the treatment of B-cell disorders, however, is rapidly evolving. Ongoing clinical trials aim at comparing CAR T cells with standard treatment options and at evaluating their efficacy earlier in the disease course. The use of CAR T cells is still limited by the risk of relevant toxicities, most commonly cytokine release syndrome and neurotoxicity, whose management has nonetheless significantly improved. Some patients do not respond or relapse after treatment, either because of poor CAR T-cell expansion, lack of anti-tumor effects or after the loss of the target antigen on tumor cells. Investigators are trying to overcome these hurdles in many ways: by testing constructs which target different and/or multiple antigens or by improving CAR T-cell structure with additional functions and synergistic molecules. Alternative cell sources including allogeneic products (off-the-shelf CAR T cells), NK cells, and T cells obtained from induced pluripotent stem cells are also considered. Several trials are exploring the curative potential of CAR T cells in other malignancies, and recent data on multiple myeloma and chronic lymphocytic leukemia are encouraging. Given the likely expansion of CAR T-cell indications and their wider availability over time, more and more highly specialized clinical centers, with dedicated clinical units, will be required. Overall, the costs of these cell therapies will also play a role in the sustainability of many health care systems. This review will focus on the major clinical trials of CAR T cells in B-cell malignancies, including those leading to the first FDA approvals, and on the new settings in which these constructs are being tested. Besides, the most promising approaches to improve CAR T-cell efficacy and early data on alternative cell sources will be reviewed. Finally, we will discuss the challenges and the opportunities that are emerging with the advent of CAR T cells into clinical routine.

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice

CAR T-cell immunotherapy of B-cell malignancy: the story so far

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Driving CAR T-cells forward

CAR T‐cell therapy: Full speed ahead

Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice

Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review

CAR T-cell Immunotherapy: a Powerful Weapon for Fighting Hematological B-cell Malignancies

CAR T cell immunotherapy in hematology and beyond

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Current Clinical Application of the CAR-T Cell Therapy

Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion